Trials / Unknown
UnknownNCT02334904
Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- University of British Columbia · Academic / Other
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Accepted
Summary
Significant changes in brain morphology are observed in people with first-episode psychosis. Studies have shown that total brain volume and particular brain structures are decreased in people with psychosis disorders. Recent evidence suggests that some atypical antipsychotic drugs can maintain or increase brain volumes. Thus, we plan to use MRI scans to measure changes in brain morphology in subjects recently diagnosed with bipolar or psychosis disorders who are taking the atypical antipsychotic drugs aripiprazole or risperidone. Secondary objectives include taking blood samples for fasting metabolic indices and neuropsychiatric measures for comparisons between drug treatments.
Detailed description
The purpose of this study is to use a direct measure of brain volume and matter (by means of MRI) to determine if there is a differential effect between aripiprazole and risperidone on brain morphology in participants with first-episode psychosis. A secondary objective is to see if fasting metabolic indices measured in the blood (i.e. glucose, insulin, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, adiponectin and leptin) are also correlated to changes in brain morphology or symptom severity (as measured by neuropsychiatric assessments).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aripiprazole | To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study) |
| DRUG | Risperidone | To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study). |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2016-06-01
- Completion
- 2016-06-01
- First posted
- 2015-01-08
- Last updated
- 2016-06-01
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02334904. Inclusion in this directory is not an endorsement.